Myocarditis elicits dendritic cell and monocyte infiltration in the heart and self-antigen presentation by conventional type 2 dendritic cells by Van Der Borght, Katrien et al.
ORIGINAL RESEARCH
published: 21 November 2018
doi: 10.3389/fimmu.2018.02714
Frontiers in Immunology | www.frontiersin.org 1 November 2018 | Volume 9 | Article 2714
Edited by:
Matthew Griffin,
National University of Ireland Galway,
Ireland
Reviewed by:
Francesca Fallarino,
University of Perugia, Italy
Yifan Zhan,
Walter and Eliza Hall Institute of
Medical Research, Australia
Sven Burgdorf,
Universität Bonn, Germany
*Correspondence:
Bart N. Lambrecht
bart.lambrecht@ugent.be
Specialty section:
This article was submitted to
Antigen Presenting Cell Biology,
a section of the journal
Frontiers in Immunology
Received: 07 May 2018
Accepted: 05 November 2018
Published: 21 November 2018
Citation:
Van der Borght K, Scott CL,
Martens L, Sichien D, Van Isterdael G,
Nindl V, Saeys Y, Boon L, Ludewig B,
Gillebert TC and Lambrecht BN (2018)
Myocarditis Elicits Dendritic Cell and
Monocyte Infiltration in the Heart and
Self-Antigen Presentation by
Conventional Type 2 Dendritic Cells.
Front. Immunol. 9:2714.
doi: 10.3389/fimmu.2018.02714
Myocarditis Elicits Dendritic Cell and
Monocyte Infiltration in the Heart and
Self-Antigen Presentation by
Conventional Type 2 Dendritic Cells
Katrien Van der Borght 1,2, Charlotte L. Scott 1,3, Liesbet Martens 1,2,3, Dorine Sichien 1,3,
Gert Van Isterdael 1,2,3, Veronika Nindl 4, Yvan Saeys 1,2, Louis Boon 5, Burkhard Ludewig 4,
Thierry C. Gillebert 2 and Bart N. Lambrecht 1,2,6*
1 Immunoregulation and Mucosal Immunology, VIB-UGent Center for Inflammation Research, Ghent, Belgium, 2Department
of Internal Medicine, Ghent University, Ghent, Belgium, 3Department of Biomedical Molecular Biology, Ghent University,
Ghent, Belgium, 4 Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland, 5 Bioceros, Utrecht,
Netherlands, 6Department of Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands
Autoimmune myocarditis often leads to dilated cardiomyopathy (DCM). Although
T cell reactivity to cardiac self-antigen is common in the disease, it is unknown
which antigen presenting cell (APC) triggers autoimmunity. Experimental autoimmune
myocarditis (EAM) was induced by immunizing mice with α-myosin loaded bone marrow
APCs cultured in GM-CSF. APCs found in such cultures include conventional type
2 CD11b+ cDCs (GM-cDC2s) and monocyte-derived cells (GM-MCs). However, only
α-myosin loaded GM-cDC2s could induce EAM. We also studied antigen presenting
capacity of endogenous type 1 CD24+ cDCs (cDC1s), cDC2s, and MCs for α-myosin-
specific TCR-transgenic TCR-M CD4+ T cells. After EAM induction, all cardiac APCs
significantly increased and cDCs migrated to the heart-draining mediastinal lymph node
(LN). Primarily cDC2s presented α-myosin to TCR-M cells and induced Th1/Th17
differentiation. Loss of IRF4 in Irf4fl/fl.Cd11cCremice reduced MHCII expression on GM-
cDC2s in vitro and cDC2 migration in vivo. However, partly defective cDC2 functions in
Irf4fl/fl.Cd11cCre mice did not suppress EAM. MCs were the largest APC subset in the
inflamed heart and produced pro-inflammatory cytokines. Targeting APC populations
could be exploited in the design of new therapies for cardiac autoimmunity.
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INTRODUCTION
In acute myocarditis immune and inflammatory cells infiltrate the heart, causing damage
to cardiomyocytes, transient heart failure and life threatening arrhythmias (1). Whereas
cardiac inflammation often disappears spontaneously, a subset of patients progresses to dilated
cardiomyopathy (DCM) and chronic heart failure with high mortality (2, 3). Acute myocarditis
is traditionally triggered by coxsackie B3 (CVB3) infection that directly destroys cardiomyocytes
as part of their replicative lytic cycle (4). As adaptive immunity can be triggered by infection
or release of danger associated molecular patterns (DAMPs) from dying cells, there is inherent
risk of autoimmunity following acute myocarditis. Organ-directed autoimmunity perpetuates
inflammation and is a risk factor for DCM development as a result of continuing myocardial
injury (5).
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Self-reactive T cells are usually removed during thymic
negative selection. However, CD4+ T cells directed against
cardiac α-myosin that escape this checkpoint, enter the periphery
and become part of the normal T cell repertoire in healthy mice
and humans (6, 7). To prevent autoimmunity, it is critical to keep
these heart-reactive T cells in a quiescent state by mechanisms
of peripheral tolerance (8, 9). Infection of the heart with CVB3
virus can however activate α-myosin specific autoreactive CD4+
T cells that infiltrate the heart and produce IL-17 (10). To
distinguish the infectious from the autoimmune phase, mouse
models of experimental autoimmune myocarditis (EAM) have
been established in which cardiac-specific T cell activation is
initiated by immunization with heart self-antigen in adjuvant
systems. In these highly immunogenic models, CD4+ T cells are
critical for the induction of EAM (11).
Activation of autoreactive CD4+ T helper cells is strongly
regulated by dendritic cells (DCs). In steady state, DCs maintain
peripheral tolerance by rendering autoreactive T cells anergic or
converting naïve T cells into induced regulatory T cells (iTreg)
(12). However, when tissues are inflamed or when the activation
threshold of DCs is genetically altered, DCs activate self-reactive
T cells which leads to autoimmunity (13–17). The potential of
DCs to initiate cardiac autoimmunity is supported by the ability
of LPS-matured bone marrow derived DCs (BMDC) loaded with
an immunogenic peptide derived from cardiac α-myosin heavy
chain (αMyHC614−629) or apoptotic cardiomyocytes to induce
EAM in wild type (WT) mice (18–21).
Although the BMDC-induced EAM model pointed to an
important role for DCs as inducers of cardiac autoimmunity,
it is still unclear what role endogenous heart DCs play in the
onset and progression of disease (9). We now realize that there
is considerably more heterogeneity in DCs and more overlap
with macrophages (MFs) than initially thought, which has led
to new classification systems of DCs into conventional DC type
1 (cDC1), conventional DC type 2 (cDC2), plasmacytoid DCs
(pDC) and monocyte-derived cells (MCs), which can function as
DCs and/or MFs (22–26). Although DCs and MFs are present in
the heart of all species studied (27–32), a detailed study of cardiac
DC and MC subsets and their implication in autoimmunity is
lacking. We have also come to realize that BMDCs such as
those used to initiate the EAMmodel (18–21) are heterogeneous,
consisting of both GM-cDCs and GM-MCs (33, 34). Therefore,
the precise role of DC subsets and MCs in the initiation and
progression of EAM is unclear at present.
Here we investigated the function of endogenous heart APC
subsets and their contribution to regulating the heart-specific
immune response by using α-myosin-specific CD4+ T cell
receptor (TCR) transgenic T cells (TCR-M cells) as readout
of antigen presenting function (35), and induction of EAM as
readout of pathogenic autoimmunity. By carefully sorting GM-
cDC and GM-MC subsets from BMDC cultures, we conclusively
show that mature GM-cDCs are the main drivers of autoimmune
T cell attack and induction of EAM. Endogenous cDC and
MC subsets were separated during EAM in heart and draining
lymph node (LN) and were used for studying gene expression
profiles by RNA sequencing. The transcriptome of cardiac APCs
revealed a superior role in self-antigen presentation for cDC2s
as was also confirmed by ex vivo co-cultures. By using mice that
genetically lack the key transcription factor (TF) IRF4 affecting
cDC2 function, we show that cDC2s lacking IRF4 can still
partially migrate to the mLN and present αMyHC to TCR-M
cells. Reduced cDC2 migration has no impact on EAM severity
suggesting that the remaining migratory cDC2s are sufficient
for sustaining EAM. Endogenous cardiac MCs are potentially
required for EAM by producing pro-inflammatory cytokines and
chemokines. Thus, interfering with the function and activation of
MCs could help in treating or preventing cardiac autoimmunity.
MATERIALS AND METHODS
Mice
Wild type (WT) Balb/c mice were purchased from Harlan
and Janvier. αMyHC-TCR transgenic mice (TCR-M) on Balb/c
background were previously described (35). Irf4fl/fl.Cd11cCre
mice were backcrossed onto the Balb/c background for at least
2 generations.
The age of the mice at use was 5–7 weeks, and mice were
housed in SPF conditions. The animal ethics committee of VIB
Inflammation Research Center and University Hospital Ghent
approved all experiments.
GM-CSF Cultures
Bone marrow cells were freshly isolated from femur and tibia
by crushing in RPMI 1640 medium. 3 × 106 bone marrow cells
were cultured in petri dishes in 10ml of tissue culture medium
(TCM) (RPMI 1640, glutamax, gentamycin, 2-mercaptoethanol,
5% heat-inactivated fetal calf serum), and GM-CSF (20 ng/ml,
in house generated) and placed at 37◦C and 20% O2/5%
CO2. 10ml of new TCM was added at day 3 of culture and
at day 6 half of the medium was refreshed. BMDCs were
harvested on day 10 by collecting the 20ml of culture medium
and washing with 5ml PBS/EDTA (15 min−37◦C) (50µM).
In some experiments, BMDCs were in vitro labeled with cell
proliferation dye eFluor450 (ebioscience) before intraperitoneal
(i.p.) injection.
Induction of Myocarditis
BMDC-induced EAM was performed with minor modifications
of an established protocol (19). On day 10 of GM-CSF
culture, BMDCs were pulsed with synthetic α-Myosin Heavy
Chain peptide (αMyHC614−629 at 15µg/ml) or ovalbumin
peptide (OVA323−339) (custom made, Pepscan) and matured
with 100 ng/ml LPS (ultra-pure lipopolysaccharide from E. coli
0111:B4 strain; InvivoGen) and 5µg/ml of agonistic antibodies
(Abs) to CD40 (clone FGK45, Bioceros) for 4 h. To initiate EAM,
mice were i.p. injected with 5 × 105 to 1 × 106 BMDCs at
day 0, 2, and 4. As a negative control, mice received mature
OVA323−339 pulsed BMDCs. GM-DCs, and GM-MCs FACS
purified from bulk BMDC cultures were also used to induce
EAM. After cell sorting, GM-DCs and GM-MCs were antigen
loaded and matured for 4 h in complete TCM with GM-CSF
(20 ng/ml), αMyHC614−629 (15µg/ml), LPS (100 ng/ml) and
αCD40 antibodies (5µg/ml). WT mice were injected i.p. with 8
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× 105 to 1 × 106 GM-DCs or GM-MCs at day 0, 2 and, 4 for
priming EAM.
Tissue Digestion
Heart left and right ventricles were flushed with PBS. Organs
were manually cut in 0.5mm pieces using scissors. Samples were
enzymatically digested with 20µg/ml liberase TM research grade
(Roche) and 10U DNase (Roche) in RPMI 1640 medium for 30–
45min at 37◦C. Digested tissues were filtered through 70µm
cell strainer to remove undigested tissue and to obtain single
cell suspensions. Osmotic lysis buffer was added for 3min to
remove erythrocytes. Tissue cell suspensions were then used as
the starting source of material for flow cytometry labeling and
cell sorting.
Flow Cytometry Labeling and Cell Sorting
Single cell suspensions from tissues or BMDC cultures were
incubated with a mix of fluorescently-labeled monoclonal Abs
for 30min at 4◦C. To reduce non-specific binding, 2.4G2 Fc
receptor Ab was added. Following Abs were used: anti-CD11c
(clone N418), anti-MHCII (clone M5/114), anti-CD11b (clone
M1/70), anti-PD-L2 (clone 122), anti-CD40 (clone 3/23), anti-
CD80 (clone 16-10A1), anti-CD86 (clone PO3), anti-CD26
(clone H194-112), anti-CD115 (clone AFS98), anti-CCR7 (clone
4B12), anti-CD25 (clone PC61), anti-CD44 (clone IM7), anti-
V alpha 2 chain (clone B20.1), anti-V beta 8.1 8.2 chain
(clone MR5-2), anti-CD3 (clone 145-2C11), anti-CD4 (clone
RM4-5), anti-CD45.2 (clone 104), anti-CD19 (clone 1D3), anti-
Ly6C (clone AL-21), anti-Ly6G (clone 1A8), anti-CD64 (clone
X54-5/7.1), anti-CD172α (clone P84), anti-XCR-1 (clone ZET),
anti-CD8α (clone 53-6.7), anti-CD24 (clone M1/69), anti-T-bet
(clone 4B10), anti-RoRγt (clone Q31-378), anti-Foxp3 (clone
FJK-16s), anti-IFNγ (clone XMG1.2), anti-IL-17A (clone TC11-
18H10), anti-CD317 (clone 120G8), anti-B220 (clone RA3-
6B2), anti-IRF4 (clone M-17). To gate out dead cells, we
used fixable viability dye eFluor 506 (eBioscience). To detect
intracellular cytokines, cells were stimulated with phorbol 12-
myristate 13-acetate (PMA, Sigma), ionomycin (Sigma) and
Golgistop Protein Transport Inhibitor (BD) for 4–5 h at 37◦C.
For intracellular cytokine staining, cells were fixed using a
fixation/permeabilization kit (eBioscience) according to the
manufacturer’s protocol. Flow cytometry was performed on a
LSR Fortessa cytometer (BD Biosciences). For cell sorting, a
FACSAria high-speed sorter (BD Biosciences) was used. Final
analysis and graphical output were performed using FlowJo
software (Tree Star, Inc.).
Adoptive Transfer of TCR-M Cells
Spleens were collected from TCR-Mmice and were mechanically
disrupted on a 70µm cell strainer. Naïve TCR-M splenocytes
were MACS purified using CD4+CD62L+ T Cell isolation kit
(Miltenyi). TCR-M cells were stained with carboxyfluorescein
succinimidyl ester (CFSE, Invitrogen). 1× 106 naïve TCR-M cells
were injected intravenously (iv.) in the lateral tail vein into WT
steady state mice. One day later, bulk BMDCs (1 × 106), sorted
GM-DCs (2 × 105) or GM-MFs (2 × 105) loaded with OVA
or αMyHC were i.p. injected. After 3 days, mice were sacrificed
and inguinal LN from the injected and opposite side, axillary
LN (injected side), mesenteric LN, mediastinal LN, spleen, and
heart were isolated. Individual cell suspensions were prepared by
mechanical disruption and stained for flow cytometry.
Co-cultures of Sorted DC Subsets and
TCR-M Cells
For ex vivo co-cultures, tissues were collected from steady state
mice and mice on day 10 of EAM. DC subsets were sorted as
described above. For co-cultures with in vitro BMDCs, GM-
DCs, and GM-MCs were sorted from bulk BMDC cultures.
TCR-M cells were labeled with carboxyfluorescein succinimidyl
ester (CFSE, Invitrogen) or with cell proliferation dye eFluor450
(ebioscience) to track their proliferation. 5 × 104 labeled TCR-
M CD4+ T cells were added to the sorted DC subsets in a 1
in 5 DC/T cell ratio in complete TCM medium. In some wells
15µg/ml of αMyHC614-629 or dead cardiomyocytes were added
to the medium. To obtain cardiomyocytes, CD45+ leukocytes
were removed by CD45MACS positive selection (Miltenyi) from
a single cell suspension of steady state heart. Per well, 5% of 1 total
digested heart was added. CFSE dilution and T cell activation
were evaluated by flow cytometry after 3–4 days. IL-17A and
IFNγ ELISA (eBioscience, Ready-Set-Go kit) was performed on
the co-culture cell supernatants (collected on day 3–4) according
to the manufacturer’s protocol.
Real-Time PCR
DC subsets were sorted from at least 10 pooled hearts on
day 10 of the EAM protocol. Sorted cells were pelleted and
suspended in TriPure isolation reagent (Roche). RNA extraction
was performed following manufacturer’s protocol. Transcriptor
high fidelity cDNA synthesis kit with random hexamer primers
(Roche) was used to reverse transcribe 500 ng RNA into cDNA.
cDNA was diluted 6–17,5 times in ultrapure water for use in
RT-PCR reactions. RT-PCR primers for used targets have been
described (36). RT-PCR reaction was performed with sensiFAST
Sybr no-ROX mix (Bioline) and was performed in triplicate in a
Roche LCII 480. Relative expression of targets was calculated by
comparison to HPRT and SDHA expression in qBase+ software
(Biogazelle, Gent, Belgium).
RNA Sequencing
cDC1s, cDC2s, CD11c+ MC, and CD11c− MCs were sorted
by FACS from 100 pooled steady state and 12 pooled inflamed
hearts (EAM day 10) of female WT Balb/c mice. 20,000 cells
were sorted straight into 500 µl buffer (RLT Plus; Qiagen) and
5 µl β-mercaptoethanol and RNA was isolated by a micro-
RNA isolation kit (Qiagen). RNA was amplified by SmarTER
amplification (Clontech) because RNA amounts were low. RNA
sequencing was performed at the Nucleomics facility (VIB,
Leuven) using NextSeq sequencer (Illumina). Trimmomatic was
used for the preprocessing of the data and adapters were cut off.
Reads were clipped when the quality dropped below 20 and were
excluded when longer than 35. FastQC was performed and all
samples passed quality control. Reads were plotted to the mouse
reference genome via Tophat2 and calculated via HTSeqCount.
R/Bioconductor was utilized to analyze the samples and data
normalization was performed using the DESeq2 procedure. To
identify unique cDC2 genes we filtered the normalized log2
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expression table using the R package “sqldf”. Log2 expression of
cDC2s from MI heart needed to be at least 1.2 log2 value bigger
than cDC2s from steady state heart. The differences between the
other steady state and EAM samples needed to be lower than 0.3
log2 value.
Ultrasound
Transthoracic echocardiography was performed using a 38 MHz
probe and a Vevo 2100 Ultrasound machine (Visualsonics). The
mice’s chests were shaved using VEET and mice were lightly
anesthetized with 0.7–1.5% isoflurane. Heart rate was conserved
at 400–500 beats per min. At least three M-mode images of the
short axis at mid-ventricular level were recorded. Diastolic and
systolic internal ventricular septum thickness (IVS, d and IVS,
s), diastolic and systolic left ventricular posterior wall thickness
(LVPW, d and LVPW, s) and left ventricular end-diastolic and
end-systolic internal diameter (LVID, d and LVID, s) were
measured using Vevo 2100 1.5.0 software. Per short axis M-mode
image, dimensions of three cardiac cycles were averaged. In total,
three independent M-mode images were used for heart function
measurements.
Statistical Analysis
For all experiments, the difference between groups was calculated
using the Mann-Whitney U-test for unpaired data (GraphPad
Prism version 6.04, San Diego, CA). Differences were considered
significant when P < 0.05.
RESULTS
Transfer of Bone Marrow cDC2s Initiates
EAM
EAM was initiated in WT Balb/c mice by immunization with
in vitro GM-CSF-derived bulk BMDCs loaded with cardiac
αMyHC614−629 peptide according to a published protocol
(Figure 1A) (19). BMDCs were matured by TLR4 stimulation
and CD40 triggering. Only mice receiving three intraperitoneal
(i.p.) αMyHC614−629-loaded BMDC injections (day 0, 2, and
4) but not those receiving control OVA323−339 peptide pulsed
BMDCs developed severe EAM characterized by massive and
patchy infiltration of leukocytes in the heart 10 days after the
first immunization (Figure 1A). In some patients, the initial
phase of autoimmune myocarditis can progress to DCM. In
our hands, immunization with αMyHC via BMDCs elicits a
mild DCM with dilation of the left ventricle in systole (LVID,
sys) (Supplementary Figures 1A,B), decrease in ejection fraction
(EF) (Supplementary Figure 1C) and increase in heart/body
weight ratio (Supplementary Figure 1D) without high mortality
(Supplementary Figure 1E).
Recently it was observed that CD11c+MHCII+ BMDCs
grown in GM-CSF are not a uniform population but consist
of conventional DCs (GM-cDCs) and monocyte-derived cells
(GM-MCs) with a macrophage-like phenotype in C57Bl/6 mice
(34). We found the same heterogeneity in Balb/c BMDC cultures
(Figure 1B). CD11c+MHCIIint cells expressed higher amounts
of the macrophage marker CD115 (receptor for Macrophage
Colony-Stimulating Factor) and were named GM-MCs, whereas
MHCIIhi cells expressed the cDC specific marker CD26 (24)
and were termed GM-cDCs. These GM-cDCs also expressed
CD172α, high levels of the transcription factor IRF4, and low
levels of IRF8 (Supplementary Figure 2A) suggesting they were
of the cDC2 lineage and were termed GM-cDC2s to stress
their cDC2 phenotype. GM-cDC2s were in a more mature state
compared to GM-MCs as demonstrated by their higher surface
expression of PD-L2, CD40, CD86 and CCR7 (Figure 1B). It
is unclear if GM-cDC2s and GM-MCs have distinct ability to
induce EAM. Similar to bulk BMDCs, 12 h after i.p. injection,
fluorescently labeled, and sorted GM-cDC2s and GM-MCs
(Supplementary Figure 2A) both migrated to the mediastinal
LN (mLN) (Figure 1C), the LN draining the peritoneum, heart
and lung (37, 38). To probe for antigen presenting capacity,
GM-cDC2s, and GM-MCs were loaded with αMyHC614−629
peptide, placed in co-culture with CFSE labeled TCR-M cells,
where both showed similar capacity to induce proliferation
(Figure 1D).Peptide can readily bind to MHCII on APCs,
therefore the uptake and processing of dead cardiomyocytes
by GM-cDC2s and GM-MCs was also tested. Both GM-cDC2s
and GM-MCs induced proliferation of TCR-M cells when dead
cardiomyocytes were added to the co-culture with labeled TCR-
M cells (Supplementary Figure 2B). GM-MCs were even slightly
better than GM-cDC2s in activating TCR-M cells. These data
suggest that the different cell types in the GM-CSF BMDC
cultures have comparable antigen processing and presenting
capacities at least in vitro.
To verify the ability of i.p. injected BMDC subsets to
prime TCR-M cells in vivo, we transferred naïve CFSE+
TCR-M cells into WT mice 1 day prior to i.p. BMDC
administration. After 3 days, TCR-M cells proliferated in the
mLN of non-injected (Supplementary Figure 2E) and OVA
BMDC injected mice (Supplementary Figures 2C,D) showing
that endogenous αMyHC is presented in the heart-draining
mLN without any cardiac damage (8, 35). Nevertheless, mice
injected with αMyHC-loaded BMDCs displayed more TCR-
M activation in mLN (Figure 1E) due to the additional
presentation of αMyHC on injected BMDCs. Some bystander
activation of TCR-M cells was observed in mesenteric LN,
spleen and inguinal LN at injection side, but only limited
proliferation was detected (Supplementary Figures 2C,D). I.p.
injection of myosin peptide loaded GM-cDC2s and GM-MCs
induced greater CD25 expression on TCR-M cells than OVA
loaded BMDCs (Figure 1E). However, GM-MCs induced less
proliferation than GM-cDC2s and bulk BMDCs in vivo. Lastly,
we evaluated the ability of GM-cDC2s and GM-MCs to elicit
EAM in vivo. Immunization with αMyHC-loaded GM-MCs
failed to induce severe EAMwhereas αMyHC-loaded GM-cDC2s
triggered EAM at levels comparable with αMyHC bulk BMDCs,
reflected by the presence of various inflammatory cells in the
heart (Figure 1F). Thus, within GM-CSF cultured bulk BMDCs,
GM-cDC2s have the potency to initiate EAM whereas GM-MCs
do not.
DC Subsets Accumulate in Heart and mLN
During EAM
Data about the functional contribution of endogenous
counterparts of the bone marrow GM-cDC2s and GM-
MCs in progression of EAM are currently lacking. cDCs are
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FIGURE 1 | Transfer of bone marrow cDC2 initiates EAM. (A) Schematic overview of BMDC-induced mouse model of experimental autoimmune myocarditis (EAM).
GM-CSF derived BMDCs were matured using LPS and αCD40 and loaded with heart specific self-antigen αMyHC614−629 or the harmless OVA323−339 antigen.
αMyHC614−629 BMDC immunization leads to fulminant myocarditis (bottom, red arrows) as shown by heamatoxylin and eosin staining of heart sections at day 10
post-immunization, whereas OVA BMDC immunization does not (top). RV, Right Ventricle; LV, Left Ventricle. (B) Flow cytometric analysis of GM-CSF derived BMDCs
harvested at day 10 of culture. Histograms display expression of the specified markers by MHCIIint GM-MCs and MHCIIhi GM-cDC2s. (C) Cell trace+ cell
percentages of total living cells in mLN of i.p. injected mice with 0.5 × 106 cell trace-labeled BMDCs, GM-cDC2s, GM-MCs, or PBS 12 h before sacrifice. (D)
Histograms representing CFSE dilution of TCR-M cells co-cultured with bulk BMDCs, sorted GM-cDC2s, or sorted GM-MCs with or without 15µg/ml αMyHC614−629
(respectively, non-filled and filled histograms) in a 1/5 DC/TCR-M ratio. (E) 4 days after naïve TCR-M injection and 3 days after OVA-loaded BMDC, αMyHC-loaded
BMDC, GM-cDC2, or GM-MC injection, mediastinal LN was isolated. CFSE dilution and CD25 expression of donor TCR-M cells was analyzed by flow cytometry. (F)
Leukocyte, T cell, neutrophil, macrophage and DC percentages of total living cells in the heart of OVA BMDCs, αMyHC BMDC, αMyHC GM-cDC2, and αMyHC
GM-MC injected mice at day 10 post-injection. All bar graphs in this figure shows data as the mean ± SEM; *P ≤ 0.05.
divided into cDC1s and cDC2s that arise from a DC-committed
hematopoietic progenitor. cDC1s depend on transcription factor
IRF8 (39) and are superior at cross-presenting exogenously
acquired antigens to CD8+ T cells (40). Tissue cDC2s depend
partly on IRF4 (41), require IRF4 for migration to the LN
and are specialized in presenting antigens in the context of
MHCII to CD4+ T cells (42). Monocytes entering tissues can
start to express CD11c and MHCII and take on DC functions,
for which they were historically named monocyte-derived
DCs (moDCs), although recent lineage tracing strategies
have shown that these cells also closely resemble MFs
(25, 43).
Cardiac CD11c+ cells were identified amongst live non-
autofluorescent CD45+ Lineage− cells (Figure 2A). cDCs were
separated from MCs by the MF marker CD64. cDCs were
further subdivided into CD24+ cDC1s and CD172α+ cDC2s and
MCs uniformly expressed CD172α. 10 days after immunization,
all cDC, and MC subsets increasingly infiltrated the heart of
αMyHC BMDC injected mice compared with OVA controls
(Figures 2A–C). MCs contributed 84% of CD11c+MHCII+ cells
in EAM day 10 heart (Figure 2C). During the DCM phase
(day 25), cDC1s returned to baseline levels while cDC2s and
MCs remained elevated compared to OVA-BMDC injected mice
(Figure 2B).
To prime naïve autoreactive CD4+ T cells, heart-resident
DCs need to migrate in a chemokine receptor CCR7-dependent
manner to the draining mLN to present self-antigen, and in
this process upregulate MHCII expression. MHCIIhi migratory
and MHCIIint LN-resident cDCs and MCs were increased in
mLN at EAM day 10 (Figure 2D). Increase of these cells was
exclusive to the mLN as DCs in skin draining inguinal LN
remained stable (Figure 2D). All subsets of cDCs and MCs were
enriched in mLN but MHCIIhi cDC2s were the largest subset
(Figure 2E). Migratory MHCIIhi cDC1s and cDC2s expressed
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FIGURE 2 | DC subsets accumulate in heart and mLN during EAM. (A) Representative flow cytometry gating strategy for cDCs, CD11c+ MCs, cDC1s, and cDC2s in
the heart of OVA or αMyHC BMDC injected WT mice on day 10 post-injection. Numbers specify cell percentage inside nearby gates. (B) Absolute cell numbers of
cDC1s, cDC2s, and MCs in the heart of OVA (pooled data of day 10 and day 25 post-inj.) and αMyHC BMDC (at day 10 and day 25 post-inj.) injected WT mice as
assessed by flow cytometry. (C) Pie charts depicting the distribution of APC subsets in heart of OVA (pooled data of day 10 and day 25 post-inj.) and αMyHC BMDC
(at day 10 and day 25 post-inj.) injected WT mice. Pie chart sizes are proportional to total absolute cardiac APC numbers. (D,E) Absolute numbers of MHCIIint and
MHCIIhi DCs (D) and MHCIIint and MHCIIhi subsets (E) in the heart-draining mediastinal LN (D,E) and skin-draining inguinal LN (D) of OVA and αMyHC BMDC
injected WT mice at day 10 post-injection. (F) Illustrative flow cytometry gating strategy for MHCIIint and MHCIIhi CD11c+ cells and CCR7 expression of MHCIIhi
cDC1s, MHCIIhi cDC2s, MHCIIhi MCs, and MHCIIint cDCs in mLN of αMyHC BMDC injected WT mice at day 10. All bar graphs in this figure shows data as the mean
± SEM; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
CCR7 while MHCIIint LN-resident cDCs lacked CCR7. In
contrast, MHCIIhi MCs lacked CCR7 expression showing that
they had most likely not migrated from heart to mLN, but
rather reached the mLN via the bloodstream while upregulating
MHCII (44) (Figure 2F). We conclude that endogenous
CD11c+MHCII+ APC subsets infiltrate the heart and cDCs
actively migrate from the inflamed heart to the draining LN in
EAM.
Expression Profiling of Cardiac APCs by
RNA Sequencing
To further characterize APC subsets in the inflamed heart,
cDC, and MC subsets were sorted 10 days post immunization
and were subjected to RNA-sequencing (RNA-seq) analysis. For
comparison, we also sorted CD11c−CD64+MHCII+ cardiac
MF-like MCs. By performing a principal component analysis
(PCA), we observed that PC1 corresponded to ontogeny of the
APCs whereas PC2 corresponded to the inflammatory milieu
in the EAM heart (steady state vs. EAM) (Figure 3A). Triwise
comparisons of gene expression (45, 46) revealed that expression
of hallmark cDC1 genes was conserved in cDC1s from EAM
hearts. Many hallmark cDC2 genes (45) were shared between
cardiac cDC2s and MCs in EAM mice (Figure 3B). Given that
cDCs are professional APCs, we evaluated the expression profile
of genes involved in the MHCI or MHCII pathway and genes
linked to T cell co-stimulation in heart cDCs and MCs in
steady state and EAM (day 10) (Figure 3C). In EAM, all heart
APC subsets gained expression of genes involved in the MHCI
pathway (Tapbp, Tap1, Tap2, Sec61b, Sec61g). However, cDC1s
had highest expression of Tap1 and Tap2 suggesting that they
were better in cross-presenting endogenously acquired antigens
to CD8+ T cells via the MHCI pathway. Similarly, some genes
linked to the MHCII pathway of antigen presentation including
Ifi30, Ctsc, and Ciita were increased in cDC2s and MCs from
EAM heart compared with steady state. In cDC1s from inflamed
hearts, only expression of Ciita increased. Fitting with cDC2s
being superior in presentation to CD4+ T cells via the MHCII
pathway, heart cDC2s displayed high expression of most MHCII
related genes in steady state and EAM (Ctss, Ctsh, Ifi30, Ctsc,
Lamp1, Cd74, H2-DMb1, H2-DMb2, H2-Oa, Ciita) (42). Mature
cDCs express surface co-stimulatory molecules to efficiently
activate naïve T cells. We therefore evaluated the RNA levels
of Cd40, Cd80, and Cd86 and observed that Cd40 expression
indeed increased on cDC2s and MCs in EAM compared with
steady state. On protein level, CD40 surface expression increased
on all subsets while CD80 and CD86 were only increased on
MCs in EAM hearts suggesting that all APCs but especially
MCs in the inflamed heart are in an activated state (Figure 3D).
To identify interesting genes, we assessed which genes were
differentially expressed in cDC2s from steady state compared
to EAM heart and not in the other APC subsets. We found
41 cDC2 specific DEGs (Supplementary Table 1). Wash1 (WAS
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FIGURE 3 | Expression profiling of cardiac APCs by RNA sequencing. (A) Front view of PCA of RNA-seq data from cDC1s, cDC2s, CD11c+ MC, and CD11c- MCs
in the steady state (St St) and the inflamed (EAM d10) heart. PCA was calculated using the top 15% most varying genes between cell subsets. Each dot symbolizes
one independently sorted replicate of the indicated cell population and four independent sorts were performed per subset. (B) Triwise diagrams of the gene
expression at EAM day 10. Red dots represent cDC1 (left) and cDC2 hallmark genes (right). (C) Heatmap showing the relative expression of MHCI- or
MHCII-associated genes normalized per mean expression of each gene in cardiac cDC1s, cDC2s, and CD11c+ MCs from steady state and EAM day 10 heart. (D)
Mean Fluorescence Intensity of CD40, CD80, and CD86 expression on heart DC subsets in OVA and αMyHC BMDC injected WT mice at day 10 post-injection. (E)
Graphs representing absolute expression of Wash1 and Serpbinb9, two cDC2-specific DEGs between steady state and EAM day 10 assessed by RNA-seq. All bar
graphs in this figure show data as the mean ± SEM; *P ≤ 0.05.
protein family homolog (1) in DCs is necessary for priming
of autoreactive T cells (47) and Serpinb9 (serine peptidase
inhibitor clade B member (9) is linked to DC maturation
and protects DCs from the kiss of death by cytotoxic CD8+
T cells (48, 49) (Figure 3E). In total, 5 out of 41 genes
have a clear role in the function of DCs and 7 genes are
involved in several immune functions (Supplementary Table 1).
The remaining 29 genes have different roles in cell migration
and division, metabolism, ciliogenesis or do not have a clear
role in DC function or no known molecular function at all.
Thus, gene analysis suggested that cardiac cDC2s would be
superior in stimulating autoreactive T cells and would have an
increased activation state and prolonged survival in the inflamed
heart.
cDC2s Present Self-Antigen in Heart and
Draining LN in EAM
To verify if cDC2s were superior in MHCII presentation to
CD4+ T cells as proposed by RNA-seq analysis, we FACS
purified cDC subsets and MCs from steady state or inflamed
heart (EAM d10) and cultured these with CFSE+ labeled
CD4+ TCR-M cells in the absence of exogenously added
αMyHC peptide. After 4 days of co-culture, none of the DC
subsets from steady state heart induced TCR-M proliferation,
although TCR-M cells co-cultured with cardiac cDC2s were
slightly activated as demonstrated by up-regulation of CD25,
suggestive of steady state self-antigen presentation (Figure 4A).
Heart cDC2s from inflamed EAM induced the highest degree
of proliferation and T cell activation (Figures 4A,B), whereas
cDC1s and MCs were less efficient at doing this. The cDC2s
of inflamed EAM hearts also induced most IFNγ and IL-
17A cytokine production in TCR-M cells (Figure 4C). Fitting
with the IL-17A production from TCR-M cells co-cultured
with cDC2s, cDC2s expressed the highest levels of the Th17
promoting cytokines IL-6 and IL-23p19 compared with cDC1s
and MCs (Figure 4D). In the inflamed heart in vivo, IL-17 and
IFNγ producing CD4+ T cells infiltrated the tissue (Figure 4E),
while double producing IL-17A and IFNγ CD4+ T cells and
CD25+Foxp3+ Tregs also increased in the heart in acute
EAM.
Upon recognizing peripheral antigens and danger signals
released from injured cells, APCs mature and migrate to the
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FIGURE 4 | cDC2s present self-antigen in heart and draining LN in EAM. (A) CFSE dilution and CD25 expression of TCR-M cells co-cultured for 3 days with sorted
heart DC subsets at steady state and at EAM day 10. Hearts were pooled from 100 steady state mice and 6 mice suffering from acute EAM. Data are representative
for three independent experiments. (B) Percentage of proliferation and CD25 expression of TCR-M cells from co-cultures plotted in panel A (mean ± SEM; *P ≤ 0.05;
**P ≤ 0.01). (C) After 3 days of co-culture (plotted in A), IFNγ and IL-17A (pg/ml) was measured in cell supernatant by ELISA. ELISA was performed in duplo on the
same sample (mean ± SD). (D) IL-6 and IL-23p19 mRNA expression in DC subsets sorted from at least 10 pooled hearts at EAM day 10 measured by qPCR. Relative
mRNA expression was calculated by normalization to housekeeping genes and qPCR reactions were performed in triplicate (mean ± SD). (E) Percentages of
heart-infiltrated IL-17+, IFNγ+, IL-17+/IFNγ+, and CD25+Foxp3+ CD4+ T cells of OVA (black bars) and αMyHC BMDC injected mice (gray bars) 10 days following
BMDC injection measured by flow cytometry after PMA/ionomycin restimulation (mean ± SEM; *P ≤ 0.05; **P ≤ 0.01). (F) CFSE dilution and CD25 expression of
TCR-M cells co-cultured for 3 days with sorted DC subsets of mLN at steady state and at EAM day 10. Data are representative for five independent experiments. (G)
Percentage of proliferation of TCR-M cells from co-cultures plotted in (F) (mean ± SEM; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001). (H) After 3 days of co-culture (plotted in
F), IFNγ (pg/ml) was measured in cell supernatant by ELISA. ELISA was performed in duplo on the same sample (mean ± SD).
organ-draining LN and present the antigen to T cells. The mLN
is the primary heart-draining LN (Figure 2D) so we next set
out to study if APC subsets transport the self-antigen αMyHC
to mLN and present it to autoreactive TCR-M cells. None of
the APC subsets sorted from the mLN of control mice were
able to stimulate TCR-M cells (Figure 4F). On the other hand,
migratory cDC2s from EAM mLN induced considerable TCR-
M proliferation and activation, suggestive of a superior ex vivo
capacity of cDC2s in inducing CD4+ T cell activation (50)
(Figures 4F,G). Although migratory cDC1s and resident cDC2s
from EAM mLNs were weak at inducing TCR-M proliferation
compared with migratory cDC2s, proliferation was still above
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the background seen after stimulation with APC subsets from
healthy mice (Figures 4F,G). Migratory cDC2s from mLN at
EAM d10 induced most IFNγ in TCR-M cells compared to the
other mLN DC subsets (Figure 4H). Finally, we verified that
all sorted mLN and heart APC subsets had antigen-presenting
capacities as they all induced TCR-M proliferation upon addition
of synthetic αMyHC614−629 peptide to the co-cultures, suggesting
that viability was not compromised by the isolation and sorting
procedure (Supplementary Figures 3A,B). Neither resident nor
migratory cDC subsets from skin-draining inguinal LN at EAM
d10 stimulated TCR-M cells (Supplementary Figure 3C). Thus,
cDC2s sorted from the heart and drainingmLN in acute EAM are
superior in presenting the cardiac self-antigen αMyHC ex vivo
to autoreactive TCR-M cells inducing TCR-M proliferation and
Th1/Th17 skewing.
Loss of IRF4 in CD11c+ Cells Does Not
Affect EAM Severity
Since we observed that activation of TCR-M cells was primarily
initiated by cDC2s ex vivo, we explored if cDC2s were necessary
for EAM progression in the BMDC-induced model in vivo. We
opted to use the Irf4fl/fl.Cd11cCre mice which were previously
shown to have reduced priming of CD4+ T cells and defective
cDC2 migration from lungs and skin to LNs (41) and a defect
in Th17 cell differentiation in the gut (50, 51). First, we cultured
BMDCs from Irf4fl/fl.Cd11cCre bone marrow to delineate the
role of IRF4 in GM-cDC2s and in EAM induction. CD11c Cre
efficiently floxed out Irf4 in vitro as demonstrated by decreased
IRF4 expression in GM-cDC2s and GM-MCs (Figure 5A). In
agreement with literature (42), Irf4fl/fl.Cd11cCre GM-cDC2s
displayed a drop in MHCII expression (Figure 5A). Despite
lowerMHCII expression, Irf4fl/fl.Cd11cCreGM-cDC2s could still
present αMyHC614−629 peptide to CD4
+ TCR-M cells in vitro as
efficient as Irf4fl/fl GM-cDC2s (Figure 5B). Immunization with
mature αMyHC loaded Irf4fl/fl.Cd11cCre BMDCs into WT mice
resulted in similar leukocyte infiltration in the heart compared
with Irf4fl/fl BMDCs (Figure 5C). Thus, loss of IRF4 in CD11c+
BMDCs did not affect autoreactive T cell activation in vitro and
subsequent EAM induction in vivo.
Next, Irf4fl/fland Irf4fl/fl.Cd11cCremice were immunized with
αMyHC loaded WT BMDCs. IRF4 was not required for the
accumulation of cDC2s in inflamed hearts (Figure 5D). As
observed in other organs, migratory cDC2s were significantly
decreased in the mLN of both OVA- and αMyHC-BMDC
immunized Irf4fl/fl.Cd11cCre mice (Figure 5D). However, about
25% of migratory cDC2s persisted in Irf4fl/fl.Cd11cCremLN and
we addressed if these cDC2s could still present αMyHC ex vivo.
Therefore, cDC2s were sorted from Irf4fl/fl and Irf4fl/fl.Cd11cCre
mLN (EAM d10) and cultured with TCR-M cells. Proliferation
and activation of TCR-M cells was induced to the same degree
by Irf4fl/fl and Irf4fl/fl.Cd11cCre migratory cDC2s (Figure 5E).
Similarly, expression of RoRγt, the crucial transcription factor for
Th17 cells, was equally high on TCR-M cells stimulated by cDC2s
of either genotype. Finally, we evaluated EAM severity and found
that Irf4fl/fl.Cd11cCre mice immunized with αMyHC BMDCs
had similar CD45+ leukocyte infiltration in the heart (day 10)
compared with WT littermates (Irf4fl/fl) (Figure 5F). Thus, loss
of IRF4 in CD11c+ cells has no impact on heart inflammation in
the EAMmodel.
Cardiac MCs Display Both DC and MF
Functions in EAM
The intact induction of EAM in Irf4fl/fl.Cd11cCre mice could
be due to residual cDC2 function, but could also be due
to redundancy with other DCs or MCs. MCs are by far
the largest APC subset in the inflamed heart, and share
many genes with cDC2s (Figure 3). Therefore, we performed
an in depth functional analysis of this subset. As MCs
express MHCII molecules, they might be important APCs
in the heart. However, compared to cDC2s, MCs of the
heart were less capable of inducing TCR-M proliferation
ex vivo (Figures 4A, 6A). To probe for the full potential
to present cardiac antigen upon injury to the heart, dead
cardiomyocytes were added to co-cultures of sorted heart
cDC2s or MCs (EAM d.10) with TCR-M cells. Whereas freshly
purified heart cDC2s readily presented αMyHC to TCR-M cells
(Figure 6A), T cell activation and proliferation increased upon
addition of dead cardiomyocytes. When dead cardiomyocytes
were added to heart MCs, they could fully activate TCR-
M cells as well (Figure 6A). In support of a competent
antigen presentation capacity, MCs and cDC2s expressed similar
amounts of cathepsin S (CathS), lysosomal-associated membrane
protein-1 (Lamp1) and the peptide exchanger H2DMb1,
factors typically important for presentation via MHCII
(Figure 6B).
As in other organs, MCs are poorly migratory and might
promote inflammation via chemokine and cytokine production
(36). Sorted heart MCs (EAM d.10) strongly expressed pro-
inflammatory C-C chemokine ligand 2 (CCL2) and IL-1α,
whereas neither cDC subsets did (Figure 6C) providing further
evidence that MCs play a role in EAM pathogenesis. Inducible
nitric oxide synthase (iNOS), a marker of M1 polarized
macrophages, was also highly expressed in MCs compared
with cDC subsets both at the level of mRNA and protein
(Figures 6C,D). We also looked at a more general set of
chemokine genes, and found that MCs expressed the highest
amount of mRNA of several CCL-chemokines compared with
cDC subsets at EAM day 10 (Figure 6E). These findings
suggest a previously unappreciated role for MCs in EAM
pathogenesis.
DISCUSSION
Cardiac damage induced by viral myocarditis, myocardial
infarction (MI) or cardiotoxic drugs, can be followed by
autoimmunity via activation of autoreactive CD4+ T cells.
Autoimmunity has a potential to perpetuate the inflammatory
response, which promotes progression of disease (4, 11, 19).
In many organs, DCs are considered essential for activation of
autoreactive CD4+ T cells, particularly when DCs are activated
by an inflammatory environment caused by infection or necrosis
(8, 52). It was previously shown that cardiac myosin is presented
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FIGURE 5 | Loss of IRF4 in CD11c+ cells does not affect EAM severity. (A) Histograms representing IRF4 and MHCII expression on GM-cDC2s and GM-MCs from
Irf4fl/fl and Irf4fl/fl .Cd11cCre BMDC cultures. (B) CD25+CFSE− TCR-M cell percentages of total TCR-M cells in co-culture with bulk BMDCs, sorted GM-cDC2s, and
sorted GM-MCs from Irf4fl/fl and Irf4fl/fl .Cd11cCre BMDC cultures with OVA323−339 peptide as negative control or with αMyHC614−629 peptide. (C) Absolute
CD45+ leukocyte number in the heart of WT mice immunized with OVA323−339 or αMyHC614−629 loaded BMDCs cultured from Irf4
fl/fl and Irf4fl/fl .Cd11cCre BM.
(D) APC subset percentages of total living cells in the heart and mLN of Irf4fl/fl and Irf4fl/fl .Cd11cCre mice immunized with OVA or αMyHC BMDCs (day 10) (E)
Histograms of CFSE dilution and RoRγt expression of TCR-M cells co-cultured for 4 days with sorted migratory cDC2s from mLN of Irf4fl/fl and Irf4fl/fl .Cd11cCre
mice 10 days after injection with αMyHC BMDCs. (F) CD45+ leukocyte percentage of total living cells in the heart of Irf4fl/fl and Irf4fl/fl .Cd11cCre mice immunized
with OVA or αMyHC BMDCs (day 10). All bar graphs in this figure shows data as the mean ± SEM; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
by heart-resident MHCII+ antigen presenting cells (APC) in
the normal mouse heart. EAM augmented the expression of
myosin-MHCII complexes in the inflamed heart and boosted
APC function (53). In these early studies, APCs were poorly
defined and the read-out for antigen presentation was with T
cell hybridomas, making it hard to conclude if heart APCs also
activate naïve T cells. Also MCs have been shown to infiltrate the
heart in CFA/αMyHC induced EAM (31) but the infiltration of
cDCs was not verified. Recently, there has been great progress
in unraveling the heterogeneity, origin and function of DCs and
MCs (22, 23). It was found that in vitro cultured BMDCs of
C57BL/6 mice using GM-CSF are heterogeneous and contain
cells resembling cDCs as well as MCs that more closely resemble
MFs (34). Here, in Balb/c mice, we found the same degree
of heterogeneity and two clearly distinguishable populations
of GM-cDCs and GM-MCs within BMDC cultures. Despite
comparable migration and self-antigen presentation of GM-
cDCs and GM-MCs, only GM-cDCs from these BM cultures had
the potential to induce EAM. Compared with GM-MCs, GM-
cDCs are superior in processing and presenting OVA protein to
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FIGURE 6 | Cardiac MCs display both DC and MF functions in EAM. (A) CFSE dilution and CD25 expression of TCR-M cells co-cultured for 3 days with sorted heart
cDC2s and CD11c+ MCs without and with addition of dead cardiomyocytes. Data are representative for two independent experiments with at least 10 mice per
experiment. (B) CathS, Lamp1 and H2DMb1 and (C) iNOS, IL-1α and CCL2 mRNA expression in cDC1s, cDC2s, and MCs sorted from at least 10 pooled hearts at
EAM day 10 measured by qPCR. Relative mRNA expression was calculated by normalization to housekeeping genes and qPCR reactions were performed in
triplicate. nd, not detectable. (Mean ± SD) (D) MFI of intracellular iNOS expression on heart cDC subsets and MCs in OVA and αMyHC BMDC injected WT mice at
day 10 post-injection (mean ± SEM; *P ≤ 0.05). (E) Heat map of relative expression of CCL-chemokine genes in cDC1s, cDC2s, and CD11c+ MCs sorted from EAM
day 10 hearts.
OT-II cells (34). In contrast to these findings, we did not observe
a difference between GM-cDCs and GM-MCs in processing and
presenting self-antigen derived from dead cardiomyocytes to
autoreactive T cells in vitro (Supplementary Figure 2B). This
discrepancy could be due to the difference in antigen and TCR
transgenic T cells used in our experiments. GM-cDCs do have
a higher expression of the maturation markers CD40, CD86,
and CCR7 (Figure 1B). Injected αMyHC-loaded GM-cDCs
induced more TCR-M activation in the mLN in vivo (Figure 1E).
We argue that GM-cDCs might likewise prime endogenous
autoreactive T cells more strongly potentially explaining their
superior EAM induction. GM-cDCs are phenotypically most
closely related to in vivo cDC2s because they lack the typical
cDC1 marker XCR-1 and have low IRF8 and high IRF4
expression (Supplementary Figure 2A). Endogenous ex vivo
sorted cDC2s from inflamed heart and mLN also displayed
superior autoreactive T cell activation and induced polarization
toward Th17 and Th1 effector cells. On the contrary, cDC1s
also accumulated in the heart and draining mLN, yet failed
to induce strong TCR-M activation and polarization. These
findings are in line with the general concept that cDC2s are
more specialized than cDC1s in presenting antigen to CD4+
T cells, due to expression of the antigen processing machinery
necessary for MHCII peptide loading, a finding confirmed
here with DC subsets from EAM hearts and recently also
confirmed by our own study on DCs in the infarcted heart
(8, 54).
In this model of EAM induction by BMDCs, initial
autoimmunity was induced by repeated immunization with
CD40 and LPS-matured BMDCs, yet subsequently, cardiac
endogenous cDC2s acquired a capacity to present cardiac self-
antigen ex vivo, a feature not seen with cDC2s isolated from
steady state hearts. The accumulation of cardiac cDCs and MCs
in progressing EAM was most likely caused by an amplificatory
loop of chemokine production emanating from the cardiac MCs,
which produce a large set of CCL chemokines that can recruit
DCs and monocytes to the heart, like CCL2 (55, 56). As none
of the APC subsets of healthy heart and mLN stimulated TCR-
M cells in ex vivo co-cultures, it was very likely that upon EAM
initiation, endogenous cDC2s in the inflammatory environment
took up dying cardiomyocytes and became activated and licensed
to prime autoreactive T cells at least ex vivo, as shown by the
increased expression of T cell co-stimulatory molecules and Th17
polarizing cytokines by the cardiac cDC2s. These data our in
accordance with the function of cDC2s in the infarcted heart
(8). On the other hand, MCs became competent to produce pro-
inflammatory chemokines. At this stage, we can only speculate
which signals drive the activation of endogenous cDCs and MCs.
In an environment of sterile tissue damage, heart DCs can be
activated through danger signals like biglycan and tenascin-C
(TC-C) released upon cardiac injury. These danger signals are
as potent as microbial TLR ligands (LPS) to stimulate αMyHC
loaded BMDCs to induce EAM in vivo (20, 21). TC-C KO mice
were protected from EAM suggesting that this danger signal is
critical for triggering DC activation and subsequent priming and
expansion of heart-specific CD4+ T cells.
When cultured together with TCR-M cells, sorted cDC2s were
able to induce Th1 and Th17 cytokine production, suggesting
they might be crucial for induction of cardiac autoimmunity.
Heart-infiltrating CD4+ T cells in TCR-M mice suffering from
spontaneous autoimmune myocarditis, also showed a mixed
Th1/Th17 cytokine profile (35). Like the cardiac cDC2s in this
study, IRF4-dependent CD103+CD11b+ cDC2s of the intestinal
lamina propria also produced IL-6 and IL-23 and polarized
CD4+ T cells to produce IL-17 (50). Previous studies have
shown that IL-6 and IL-23 deficient mice are resistant to EAM
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(18, 57), and results from our study now suggest that this might
be caused by defective Th17 polarization by cardiac cDC2s.
To validate this hypothesis, we set up EAM experiments in
Irf4fl/fl.Cd11cCre mice. These mice have been shown to have
defective Th17 immune response induction in mucosal tissues
(50, 51), deficits in migration of cDC2s to the draining nodes
of skin, lungs and heart (8, 26, 39, 41, 58), and a generalized
deficiency in MHCII antigen presentation (42). However, in the
EAMmodel, despite a significant reduction in cDC2migration to
themLN, Irf4fl/fl.Cd11cCremice were not protected from disease,
most likely due to the fact that residual IRF4-deficient cDC2s
were fully competent in activating TCR-M cells. Autoreactive T
cell activation following MI was also intact in Irf4fl/fl.Cd11cCre
mice (8). As cardiac cDC2s were largely unaffected by loss
of IRF4 in the EAM model and myocardial infarction, it is
also possible that cDC2s or MCs acted locally in the heart to
activate effector autoreactive CD4+ T cells. We speculated that
the injection of WT BMDCs might have bypassed the need for
IRF4 in endogenous cDC2s for EAM development. However,
we also performed experiments using immunizations with IRF4-
deficient BMDCs, and also found EAM induction to be intact
(Figure 5C). We cannot explain why we did not see the reduction
in MHCII-mediated antigen presentation that was previously
reported in IRF4-deficient DCs, except for the fact that previous
work showing this association was done using BMDCs, and
studying antigen responses in the absence of strong adjuvant
systems (42). As we show here in our RNA-seq analysis, there
are no good genes that can separate cDC2s from MCs, and until
now, no good models exist to selectively and completely delete
functional cDC2s.
The MCs accumulating in EAM hearts have been described
before, but interpretation of what these cells do varies between
authors. Previous work has shown that the NO-producing
monocytes and MCs of the heart suppress development of
DCM via production of NO and by suppression of T cell
expansion (31, 59). As observed in the lung during airway
inflammation, we speculate that heart MCs in EAM display a
MF-phenotype and are significant producers of chemokines and
cytokines, thus controlling influx of inflammatory leukocytes
and effector lymphocytes and most likely activating them
locally in conjunction with heart cDC2s (36). In support, gene
expression profiles of cardiac CD11c+ MCs in EAM greatly
resembled transcriptome of CD11c− MCs that are often called
MFs (Figure 3A). Heart CD11c+ MCs produced typical MF
cytokines like IL-1α and CCL2, the predominant chemokine
controlling influx of effector cells. In a model in which CCL2
was inactivated, EAM severity and progression toward DCMwas
reduced (60). Here, blockade of the CCL2/CCR2 axis suppressed
the downstream chemokine and cytokine cascade, suggesting
that CCR2-dependent cells like MCs were crucial in controlling
ongoing inflammation. There is certainly a possibility that once
EAM is initiated and cardiomyocytes start to die, MCs also
present cardiac antigens in situ to self-reactive T cells. This is
supported by our findings that cardiac MCs were very proficient
in presenting self-antigens from dying cardiomyocytes ex vivo.
In such an in situ antigen presenting scenario, there would also
be no need for MCs to migrate to the draining nodes, and
observation we also made in this study.
In conclusion, we have studied the contribution of various
APCs in the onset and progression of EAM, and found that
GM-cDC2s, and not GM-MCs, were able to initiate EAM.
With progression of disease, endogenous CD11c+ cells do
not require IRF4 for EAM to develop to its full extent,
and several APC subtypes are endowed with APC function.
We can only speculate that in humans a similar scenario
would be operative. In humans, DC subsets can be reliably
identified using a panel of monoclonal antibodies. Our study
suggests that is worth analyzing the distribution of DC
subsets in the diagnostic endomyocardial biopsies taken from
early cases of viral myocarditis. In the future, it might be
possible to target the function of cDC2s and MCs in an
attempt to dampen myocardial inflammation and progression
to DCM.
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Supplementary Figure 1 (related to Figure 1) | (A) 35 days following BMDC
injection, echocardiography was performed and short axis M-mode images are
shown of OVA DC injected mice and αMyHC DC injected mice. LVID dias, Left
Ventricular Internal Diameter in diastole; LVID sys, Left Ventricular Internal Diameter
in systole. (B) Graph depicting LVID in systole in groups of mice displayed in panel
A at day 35 post-immunization. (C,D) Ejection fraction (EF) (C) and heart/body
weight ratio (D) of groups of mice displayed in panel A (mean ± SEM; ∗∗P ≤ 0.01;
∗∗∗P ≤ 0.001). (E) Survival curve of groups of mice displayed in panel A. All bar
graphs show data as mean ± SEM; ∗∗P ≤ 0.01; ∗∗∗P ≤ 0.001.
Supplementary Figure 2 (related to Figure 1) | (A) Flow cytometry gating
strategy for sorting of MHCIIhiPD-L2+CD115− GM-cDC2s and
MHCIIintPD-L2−CD115+ GM-MCs from bulk BMDCs harvested at day 10 of
culture. (B) Dilution of proliferation dye eF450 and CD25 expression of TCR-M
cells co-cultured for 4 days with sorted GM-cDC2s or sorted GM-MCs with
addition of dead cardiomyocytes in a 1/10 DC/TCR-M ratio. (C) 4 days after naïve
TCR-M injection and 3 days after BMDC injection, depicted LNs and spleen were
isolated. CFSE dilution and CD25 expression of donor TCR-M cells was analyzed
by flow cytometry. (D) Percentage of proliferation and CD25 expression of donor
TCR-M cells in LNs and spleen from experiment described in (B). (E) 4 days after
naïve TCR-M injection into steady state mice (not injected with BMDCs), CFSE
dilution, and CD25 expression of donor TCR-M cells was analyzed by flow
cytometry. All bar graphs show data as mean ± SEM; ∗P ≤ 0.05.
Supplementary Figure 3 (related to Figure 4) | (A,B) CFSE dilution and CD25
expression of TCR-M cells co-cultured with sorted APC subsets of heart (shown in
A) and mLN (shown in B) at EAM day 10 with addition of 15µg/ml
αMyHC614−629 peptide. (C) CFSE dilution and CD25 expression of TCR-M cells
co-cultured with sorted DC subsets of inguinal LN at EAM day 10.
Supplementary Table 1 | List of differentially expressed genes in cDC2s from
steady state compared to EAM heart.
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